Dermatol. praxi. 2017;11(4):183-186 | DOI: 10.36290/der.2017.044

Alopecia areata – current trends in treatment

MUDr. Helena Michalíková
Dermatovenerologie, EUC Premium s. r. o., Praha

Alopecia areata is an autoimmune disease in which the choice of therapy depends on the extent of the disease and patient‘s agemainly. Local therapies are available for localized forms of the disease but have little effect on large-scale manifestations (especiallyalopecia totalis and alopecia universalis). Up to now, systemic therapy for alopecia areata is burdened with a number ofside effects and a high percentage of relapses after discontinuation. With new advances in disease mechanisms, new treatmentoptions are emerging. Particularly targeted treatment for immune mechanisms of the disease and platelet-rich plasma therapyshow promising results.

Keywords: alopecia areata, Janus kinases, platelet-rich plasma

Received: March 12, 2018; Accepted: April 3, 2018; Prepublished online: April 3, 2018; Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Michalíková H. Alopecia areata – current trends in treatment. Dermatol. praxi. 2017;11(4):183-186. doi: 10.36290/der.2017.044.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2003; 139(12): 1555-1559. Go to original source... Go to PubMed...
    2. Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008; 128(5): 1196-1206. Go to original source... Go to PubMed...
    3. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014; 20(9): 1043-1049. Go to original source... Go to PubMed...
    4. Renert-Yuval Y, Guttman-Yassky E. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm. Adv Ther. 2017; 34(7): 1594-1609. Go to original source... Go to PubMed...
    5. Finner AM. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Ther. 2011; 24: 348-354. Go to original source... Go to PubMed...
    6. Ito T. Advances in the management of alopecia areata. J Dermatol. 2012; 39(1): 11-17. Go to original source... Go to PubMed...
    7. Ustuner P, Balevi A, Özdemir M. Best dilution of the best corti-costeroid for intralesional injection in the treatment of localized alopecia areata in adults. J Dermatolog Treat 2017; 30: 1-9. Go to original source... Go to PubMed...
    8. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003; 49(1): 96-98. Go to original source... Go to PubMed...
    9. Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002; 46(2): 309-312. Go to original source... Go to PubMed...
    10. Wirta D, Pariser DM, Yoelin SG, Arase S, McMichael A, Weng E, Mao C, Demos G, Vandenburgh A. Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials. J Clin Aesthet Dermatol. 2015; 8(7): 17-29.
    11. Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017; 26(4): 515-522. Go to original source... Go to PubMed...
    12. Zaher H, Gawdat HI, Hegazy RA, Hassan M. Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study. Dermatology. 2015; 230(4): 308-313. Go to original source... Go to PubMed...
    13. Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017 Mar 16; 3: 17011. Go to original source... Go to PubMed...
    14. Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol 1983; 63: 49-52. Go to original source... Go to PubMed...
    15. Singh G, Lavanya M. Topical immunotherapy in alopecia areata. Int J Trichology. 2010; 2(1): 36-39. Go to original source... Go to PubMed...
    16. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012; 166(5): 916-926. Go to original source...
    17. Sun J, Silva KA, McElwee KJ, King LE, Sundberg JP. The C3H/HeJ mouse and DEBR rat models for alopecia areata: preclinical drug screening tools. Exp Dermatol. 2008; 17: 793-805. Go to original source... Go to PubMed...
    18. Mohamed Z, Bhouri A, Jallouli A, Fazaa B, Kamoun MR, Mokhtar I, et al. Alopecia areata treatment with a phototoxic dose of UVA and topical 8-methoxypsoralen. J Eur Acad Dermatol Venereol 2005; 19: 552-555. Go to original source... Go to PubMed...
    19. Senila SC, Danescu SA, Ungureanu L, Candrea E, Cosgarea RM. Intravenous methylprednisolone pulse therapy in severe alopecia areata. Indian J Dermatol Venereol Leprol. 2015; 81(1): 95. Go to original source... Go to PubMed...
    20. Aç?kgöz G, Ozmen I, Cay?rl? M, Yeniay Y, Köse O. Pulse methylprednisolone therapy for the treatment of extensive alopecia areata. J Dermatol Treat. 2014; 25(2): 164-166. Go to original source... Go to PubMed...
    21. Lee D, Oh DJ, Kim JW, Park SW, Oh MK, Sung HS, Hwang SW. Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids. Ann Dermatol. 2008; 20(4): 172-178. Go to original source... Go to PubMed...
    22. Hammerschmidt M, Brenner FM. Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol. 2014; 89: 729-734. Go to original source... Go to PubMed...
    23. Farshi S, Mansouri P, Safar F, Khiabanloo SR. Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study. Int J Dermatol. 2010; 49: 1188-1193. Go to original source...
    24. Ferreira SB, Scheinberg M, Steiner D, Steiner T, Bedin GL, Ferreira RB. Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report. Case Rep Dermatol. 2016; 8(3): 262-266. Go to original source... Go to PubMed...
    25. Anzengruber F, Maul JT, Kamarachev J, Trüeb RM, French LE, Navarini AA. Transient Efficacy of Tofacitinib in Alopecia Areata Universalis. Case Rep Dermatol. 2016; 8(1): 102-106. Go to original source... Go to PubMed...
    26. Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017; 76(1): 29-32. Go to original source... Go to PubMed...
    27. Craiglow BG, Tavares D, King BA. Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatol. 2016; 152(4): 490-491. Go to original source...
    28. Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, et al. A randomized, double-blind, placebo and active-controlled, half-head study to evaluate the effects of platelet rich plasma on alopecia areata. Br J Dermatol 2013; 169(3): 690-694. Go to original source... Go to PubMed...
    29. McMichael AJ. Excimer laser: a module of the alopecia areata common protocol. J Investig Dermatol Symp Proc. 2013; 16(1): 77-79. Go to original source... Go to PubMed...
    30. Mlacker S, Aldahan AS, Simmons BJ, Shah V, McNamara CA, Samarkandy S, Nouri K. A review on laser and light-based therapies for alopecia areata. J Cosmet Laser Ther. 2017; 19(2): 93-99. Go to original source...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.